

Supplementary information: Name and European license holder for the 32 new medicines approved by the EMA during 2014

Trade name	Approved (generic) name	European license holder
Adempas	riociguat	Bayer AG
Cometriq	cabozantinib	Ipsen Pharma
Cyramza	ramucirumab	Eli Lilly Nederland B.V.
Daklinza	daclatasvir	Bristol-Myers Squibb Pharma EEIG
Deltysba	delamanid	Otsuka Novel Products GmbH
Entyvio	vedolizumab	Takeda Pharma A/S
Eperzan	albiglutide	GlaxoSmithKline Trading Services Ltd
Gazyvaro	obinutuzumab	Roche Registration Ltd
Harvoni	ledispavir 90mg / sofosbuvir 400mg	Gilead Sciences International Ltd
Imbruvica	ibrutinib	Janssen-Cilag International NV
Incruse	umeclidinium bromide	Glaxo Group Ltd
Jardiance	empagliflozin	Boehringer Ingelheim International GmbH
Latuda	lurasidone	Sunovion Pharmaceuticals Europe Ltd
Lynparza	olaparib	AstraZeneca AB
Mekinist	trametinib	Novartis Europharm Limited
Moventig	naloxegol oxalate	AstraZeneca AB [note - ownership passed to Kyowa Kirin Limited after data collection].
Nuwiq	simoctocog alfa (rFVIII)	Octapharma AB

Olysio	simeprevir	Janssen-Cilag International N.V.
Plegridy	peginterferon beta-1a	Biogen Idec Ltd
Rixubis	nonacog gamma	Baxalta Innovations GmbH
Scenesse	afamelanotide	Clinuvel UK Ltd
Sirturo	bedaquiline fumarate	Janssen-Cilag International N.V.
Sovaldi	sofosbuvir	Gilead Sciences International Ltd
Sylvant	siltuximab	Janssen-Cilag International N.V.
Tecfidera	dimethyl fumarate	Biogen Idec Ltd
Tivicay	dolutegravir	ViiV Healthcare
Translarna	ataluren	PTC Therapeutics International Limited
Trulicity	dulaglutide	Eli Lilly Nederland B.V.
Vargatef	nintedanib	Boehringer Ingelheim International GmbH
Velphoro	mixture of polynuclear iron(III)-oxyhydroxide, sucrose and starches	Vifor Fresenius Medical Care Renal Pharma France
Vimizim	elosulfase alfa	BioMarin Europe Ltd
Zydelig	idelalisib	Gilead Sciences International Ltd